Southern RNA, an Australian-based Contract Development and Manufacturing Organisation (CDMO) specialising in RNA-based therapeutics and mRNA manufacturing, is delighted to announce the appointment of Chris Peck as its new Chief Executive Officer (CEO), effective immediately.

Chris transitioned from his previous role as Non-Executive Director and will now steer the company into its next dynamic phase of growth.  Chris Peck’s appointment marks a significant milestone for Southern RNA as it continues to expand its mRNA manufacturing capabilities and solidify its position as a global leader in the biotechnology sector.

With decades of senior leadership experience across biotechnology, advanced manufacturing, and scaling in highly complex international matrixed industries, Chris brings invaluable expertise in commercialisation and large-scale operational management.  His deep knowledge of international markets, including India, Korea, and the North America, will be instrumental in driving Southern RNA's continued growth.

Under Chris Peck’s leadership, Southern RNA will continue to prioritise innovation in mRNA therapeutics, with a particular focus on personalised medicine and small-scale manufacturing for clinical development.  His appointment confirms Southern RNA’s commitment to scaling up its manufacturing capabilities to meet the growing global demand for high-quality mRNA therapeutics.

“Our vision is to lead the way in biotechnology and mRNA manufacturing, both in Australia and globally,” said Chris Peck, CEO of Southern RNA. “With our cutting-edge facilities and strong partnerships with research institutions and biotech companies, we are uniquely positioned to drive innovation.  I am excited and honoured to lead Southern RNA through this period of significant growth and transformation.”

The biotechnology and mRNA manufacturing sectors continue to experience rapid growth, driven by the demand for new vaccines and personalised therapeutics. Southern RNA’s expansion plans include further investment in its GMP-certified manufacturing facilities, enabling the company to serve clients both in Australia and abroad. With Chris Peck as its leader, Southern RNA is set to accelerate its growth into new markets and strengthen its standing as a key player in the global biotechnology landscape.

Southern RNA is an Australian-based CDMO specialising in the production of nucleic acid products, including mRNA and advanced RNA-based therapeutics.  With a strong focus on quality, innovation, and collaborative partnerships, Southern RNA is committed to advancing personalised medicine and supporting clients from clinical development through to commercialisation.